SomaLogic, Inc.

SomaLogic, Inc., filing under the Nasdaq ticker CMII, submitted an 8-K with the SEC on June 9, 2023, as part of its ongoing public-company disclosure obligations following a completed de-SPAC transaction. CM Life Sciences III, the blank-check vehicle that brought SomaLogic to market, priced its IPO in 2021 and concentrated on the life sciences and healthcare technology sector. The SPAC was sponsored by CM Life Sciences III Sponsor LLC, an entity affiliated with investment firms Casdin Capital and Corvex Management. SomaLogic operates a proteomics-based platform serving diagnostic and research applications. Sign up on SpacDesk to access full filing histories, sponsor profiles, and deal-level analytics across the SPAC universe.